UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

General principles of insulin therapy in diabetes mellitus

Author
David K McCulloch, MD
Section Editor
David M Nathan, MD
Deputy Editor
Jean E Mulder, MD

INTRODUCTION

Insulin is used in the treatment of patients with diabetes of all types. The need for insulin depends upon the balance between insulin secretion and insulin resistance. All patients with type 1 diabetes need insulin treatment permanently, unless they receive an islet or whole organ pancreas transplant; many patients with type 2 diabetes will require insulin as their beta-cell function declines over time.

Indications for insulin therapy, available formulations of insulin, insulin pharmacokinetics, and determinants of efficacy will be reviewed here. The specifics of insulin therapy for type 1 and type 2 diabetes and intensive insulin therapy for critically ill patients who become hyperglycemic are discussed separately. (See "Management of blood glucose in adults with type 1 diabetes mellitus" and "Insulin therapy in type 2 diabetes mellitus" and "Glycemic control and intensive insulin therapy in critical illness".)

WHICH PATIENTS NEED INSULIN

Insulin must be given to all patients with type 1 diabetes, which is due to autoimmune islet-cell injury that eventually leads to virtually complete insulin deficiency. Ideally, physiologic replacement of insulin, imitating the secretory pattern of the nondiabetic pancreas but keeping in mind that therapeutic insulin is administered subcutaneously, is desirable. (See "Pathogenesis of type 1 diabetes mellitus".)

The peak incidence of type 1 diabetes is around the time of puberty, but approximately 25 percent of cases present after 35 years of age [1]. Insulin is also indicated for patients with secondary diabetes due to pancreatic insufficiency, as well as in many patients with type 2 diabetes to manage hyperglycemia.

Clinical features that, if present in a patient with diabetes at any age, suggest the need for insulin therapy include marked and otherwise unexplained recent weight loss (irrespective of the initial weight), a short history with severe symptoms, and the presence of moderate to heavy ketonuria. Diabetic ketoacidosis at first presentation usually indicates that the patient has type 1 diabetes and will require lifelong insulin treatment. However, some patients with type 2 diabetes, especially in the Afro-Caribbean populations (so-called "Flatbush diabetes"), may present with ketoacidosis. (See "Classification of diabetes mellitus and genetic diabetic syndromes" and "Syndromes of ketosis-prone diabetes mellitus".)

                  

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Oct 20 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Harris MI, Robbins DC. Prevalence of adult-onset IDDM in the U.S. population. Diabetes Care 1994; 17:1337.
  2. Brunton S, Carmichael B, Funnell M, et al. Type 2 diabetes: the role of insulin. J Fam Pract 2005; 54:445.
  3. Richter B, Neises G. 'Human' insulin versus animal insulin in people with diabetes mellitus. Cochrane Database Syst Rev 2005; :CD003816.
  4. Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab 2011; 13:677.
  5. Zib I, Raskin P. Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab 2006; 8:611.
  6. Owen WE, Roberts WL. Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. Clin Chem 2004; 50:257.
  7. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43:396.
  8. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21:1904.
  9. Hirsch IB. Insulin analogues. N Engl J Med 2005; 352:174.
  10. Rapid acting insulin analogs. The Medical Letter 2009; 51:98.
  11. Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008; 47:7.
  12. Giugliano D, Esposito K. Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes. Ther Adv Endocrinol Metab 2012; 3:99.
  13. Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23:644.
  14. Sanches AC, Correr CJ, Venson R, Pontarolo R. Revisiting the efficacy of long-acting insulin analogues on adults with type 1 diabetes using mixed-treatment comparisons. Diabetes Res Clin Pract 2011; 94:333.
  15. Swinnen SG, Simon AC, Holleman F, et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; :CD006383.
  16. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29:2104.
  17. Davis MD, Beck RW, Home PD, et al. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin. Exp Clin Endocrinol Diabetes 2007; 115:240.
  18. Rosenstock J, Fonseca V, McGill JB, et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia 2009; 52:1778.
  19. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52:1732.
  20. Colhoun HM, SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52:1755.
  21. Jonasson JM, Ljung R, Talbäck M, et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; 52:1745.
  22. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52:1766.
  23. Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009; 52:1971.
  24. Chang CH, Toh S, Lin JW, et al. Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study. PLoS One 2011; 6:e21368.
  25. Morden NE, Liu SK, Smith J, et al. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 2011; 34:1965.
  26. Suissa S, Azoulay L, Dell'Aniello S, et al. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011; 54:2254.
  27. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009; 52:2499.
  28. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367:319.
  29. US Food and Drug Administration. FDA Drug Safety Communication: Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer. http://www.fda.gov/Drugs/DrugSafety/ucm239376.htm (Accessed on January 17, 2011).
  30. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005; 28:1240.
  31. Ballani P, Tran MT, Navar MD, Davidson MB. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. Diabetes Care 2006; 29:2504.
  32. Davidson MB, Navar MD, Echeverry D, Duran P. U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care 2010; 33:281.
  33. http://www.fda.gov/Drugs/DrugSafety/ucm510318.htm (Accessed on October 20, 2016).
  34. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018780s135s152lbl.pdf (Accessed on February 23, 2016).
  35. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206538lbl.pdf (Accessed on March 13, 2015).
  36. Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015; 17:386.
  37. Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014; 37:2755.
  38. Yki-Järvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014; 37:3235.
  39. Roach P, Bai S, Charbonnel B, et al. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. Clin Ther 2004; 26:502.
  40. Joseph SE, Korzon-Burakowska A, Woodworth JR, et al. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. Diabetes Care 1998; 21:2098.
  41. Koivisto VA, Tuominen JA, Ebeling P. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 1999; 22:459.
  42. Woodworth JR, Howey DC, Bowsher RR, et al. Comparative pharmacokinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures. Diabetes Care 1994; 17:366.
  43. Brodows R, Chessor R. A comparison of premixed insulin preparations in elderly patients. Efficacy of 70/30 and 50/50 human insulin mixtures. Diabetes Care 1995; 18:855.
  44. Dunbar JM, Madden PM, Gleeson DT, et al. Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients. Diabetes Care 1994; 17:874.
  45. American Diabetes Association. Insulin administration. Diabetes Care 2004; 27 Suppl 1:S106.
  46. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 7:188.
  47. Sindelka G, Heinemann L, Berger M, et al. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 1994; 37:377.
  48. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23:639.
  49. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28:1107.
  50. Owens DR, Bolli GB. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther 2008; 10:333.
  51. Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983; 24:326.
  52. Taylor R, Home PD, Alberti KG. Plasma free insulin profiles after administration of insulin by jet and conventional syringe injection. Diabetes Care 1981; 4:377.
  53. Golden MP, Haymond M, Hinnen DA, et al. Position statement on jet injectors. Diabetes Care 1988; 11:600.
  54. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care 1999; 22:137.
  55. Galloway JA, Spradlin CT, Nelson RL, et al. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981; 4:366.
  56. Micossi P, Cristallo M, Librenti MC, et al. Free-insulin profiles after intraperitoneal, intramuscular, and subcutaneous insulin administration. Diabetes Care 1986; 9:575.
  57. Fleming DR, Jacober SJ, Vandenberg MA, et al. The safety of injecting insulin through clothing. Diabetes Care 1997; 20:244.
  58. Koivisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med 1980; 92:59.
  59. Klemp P, Staberg B, Madsbad S, Kølendorf K. Smoking reduces insulin absorption from subcutaneous tissue. Br Med J (Clin Res Ed) 1982; 284:237.
  60. Riccio A, Avogaro A, Valerio A, et al. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin. Diabetes Care 1994; 17:535.
  61. Koivisto VA, Felig P. Effects of leg exercise on insulin absorption in diabetic patients. N Engl J Med 1978; 298:79.
  62. Koivisto VA. Sauna-induced acceleration in insulin absorption from subcutaneous injection site. Br Med J 1980; 280:1411.
  63. Linde B. Dissociation of insulin absorption and blood flow during massage of a subcutaneous injection site. Diabetes Care 1986; 9:570.
  64. Berger M, Cüppers HJ, Hegner H, et al. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care 1982; 5:77.